« Back
Home /
PCI-32765

PCI-32765

Item no.	M1825-200mg
Manufacturer	AbMole
CASRN	936563-96-1
Amount	200mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	0,9983
Citations	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Advani RH, et al . J Clin Oncol. 2013 Jan 1,31(1):88-94. PMID: 23045577 . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. de Rooij MF, et al . Blood. 2012 Mar 15,119(11):2590-4. PMID: 22279054 . The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Chang BY, et al . Arthritis Res Ther. 2011 Jul 13,13(4):R115. PMID: 21752263 . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Honigberg LA, et al . Proc Natl Acad Sci U S A. 2010 Jul 20,107(29):13075-80. PMID: 20615965 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Ibrutinib; CRA-032765
Similar products	PCI-32765, Ibrutinib
Available
Molecular Weight	440, 5
Solubility	DMSO ≥30 mg/mL
Bioactivity information	PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1825-200mg-safety-datasheet.pdf